Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program for AML and MDS

Marker Therapeutics announced the treatment of the first patient in their Phase 1 RAPID study, evaluating MT-401, an off-the-shelf (OTS) multi-antigen...